Status:
COMPLETED
The Effect of AI-based Microbiome Diet on IBS-M Symptoms
Lead Sponsor:
Gazi University
Collaborating Sponsors:
ENBIOSIS BIOTECHNOLOGIES
TC Erciyes University
Conditions:
Irritable Bowel Syndrome Mixed
Eligibility:
All Genders
20-65 years
Phase:
NA
Brief Summary
This study was designed as a pilot, open-labelled study. We enrolled consecutive IBS-M patients (n=25, 19 females, 46.06 ± 13.11 years) according to Rome IV criteria. Fecal samples were obtained from ...
Eligibility Criteria
Inclusion
- Diagnosed with IBS by a medical doctor.
- BMI between 18.5-39.9 kg/m2
- No hospitalization in the last 12 months.
- No antibiotics use in the last 6 months.
- No cancer diagnosis by a medical doctor.
- No chronic complex diseases including diabetes and hypertension.
Exclusion
- Not being diagnosed with IBS.
- Having a diagnosed chronic disease.
- Having a diagnosed mental or psychiatric disorder .
- Having endocrinal disorders.
- Being pregnant.
- Antibiotics use in the last 6 months.
- Hospitalization history in the last 12 months.
- Drug use.
- Being morbid obese.
Key Trial Info
Start Date :
October 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 15 2021
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04768387
Start Date
October 5 2020
End Date
January 15 2021
Last Update
February 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gazi University
Ankara, Turkey (Türkiye)